Amyotrophic Lateral Sclerosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Rilutek, Edaravone ), By Treatment Type, By End-Users, By Region & Competition, 2021-2031F

Description

The Global Amyotrophic Lateral Sclerosis (ALS) Market is projected to expand from USD 787.81 Million in 2025 to USD 1127.05 Million by 2031, reflecting a CAGR of 6.15%. This market encompasses both pharmaceutical therapeutics and assistive technologies designed to manage symptoms and slow the progression of this neurodegenerative disorder. Growth is primarily propelled by an increasing prevalence of the condition within an aging demographic and the rise of precision medicine targeting specific genetic mutations. Furthermore, the sector is bolstered by significant investments in scientific research and a widening pipeline of potential treatments, evidenced by the ALS Association supporting 149 active research projects across 13 countries in 2024 to speed up drug development.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 787.81 Million
Market Size 2031	USD 1127.05 Million
CAGR 2026-2031	6.15%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Despite these advancements, the industry faces a significant hurdle due to the high attrition rate of candidates during advanced clinical trials. The intricate biological mechanisms of ALS often lead to efficacy failures in pivotal testing stages, generating uncertainty for both developers and investors. This enduring challenge postpones regulatory approvals and hinders the launch of effective therapeutic alternatives, thereby constraining potential revenue streams within the sector.

Market Driver

A major catalyst for market expansion is the escalating public and private investment in research and development, driven by the urgent need for effective disease-modifying treatments. This financial influx is essential for covering the substantial costs of clinical trials and supporting the progression of therapeutic candidates from early discovery to commercial viability. For example, in November 2024, Trace Neuroscience secured a $101 million investment to advance genomic therapies for neurodegenerative conditions into clinical phases. Similarly, the non-profit sector is crucial in de-risking early scientific exploration, as demonstrated by FightMND's commitment of an additional $18.89 million to research and care initiatives in November 2024, highlighting the strong global funding dedicated to overcoming efficacy barriers.

The second significant driver is the advancement in genetic research and precision medicine, which is fundamentally altering the industry's focus from symptom management to targeted biological interventions. Identifying specific mutations, such as those in the SOD1 gene, has facilitated the creation of antisense oligonucleotides that target the disorder's root causes. This progress enables more stratified clinical trials, potentially lowering failure rates by testing therapies on the most responsive patient groups. Illustrating this shift, LifeArc pledged £1.5 million in May 2024 to a new partnership focused on validating human genetic therapeutic targets, thereby aiming to bridge the translational gap in drug development and attract stakeholder interest in personalized solutions.

Market Challenge

The substantial attrition rate of therapeutic candidates during advanced clinical phases acts as a major barrier to the Global ALS Market's growth. This difficulty largely arises from the disease's complex and heterogeneous nature, which complicates the identification of robust biological markers for assessing drug efficacy. As a result, pharmaceutical companies often face setbacks when promising early-stage compounds fail to show statistically significant benefits in pivotal Phase III trials. These late-stage failures result in considerable financial losses due to the exponentially increasing costs of clinical development, which in turn discourages risk-averse investors and diminishes the capital inflow needed for future scientific pursuits.

This continuous cycle of failure directly limits market expansion by postponing the commercialization of viable treatments and causing bottlenecks in the product pipeline. The unpredictability regarding regulatory approval compels developers to prolong timelines and drastically raise research budgets, eroding potential profit margins and restricting the number of successful market entrants. According to the ALS Association, although there were more than 50 ALS drugs targeting various mechanisms under development in 2025, the industry's historical struggle to translate these candidates into approved therapies means the actual introduction of revenue-generating options remains minimal, directly impeding the sector's financial progress.

Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) is revolutionizing the discovery of novel therapeutic targets, effectively addressing the challenges posed by complex disease biology. By analyzing extensive genomic datasets, these platforms can predict causal mechanisms with greater precision than traditional animal models, thereby streamlining the discovery process. This approach utilizes AI-driven validation to de-risk candidate selection prior to clinical entry, ensuring that resources are directed toward compounds with the highest likelihood of success. For instance, Verge Genomics reported in November 2024 that its AI-enabled platform achieved an 83% validation rate for prioritized targets in disease-relevant models, significantly surpassing standard industry benchmarks.

Simultaneously, the incorporation of Neurofilament Light Chain (NfL) biomarkers is transforming clinical trial designs by providing an objective standard for disease monitoring. In contrast to subjective functional rating scales, NfL levels deliver a quantifiable measure of neuroaxonal damage, allowing researchers to detect patient responses to treatment with greater speed and accuracy. This methodology facilitates earlier decision-making in drug development and aids in stratifying patient populations to improve trial efficacy. As highlighted by ALS News Today in July 2024, blood-based NfL levels demonstrated the ability to accurately identify approximately 80% of ALS patients, significantly outperforming other potential protein markers in distinguishing the condition.

Key Market Players

Sanofi S.A.
Brainstorm Cell Therapeutics Inc.
Biogen Inc.
Bausch Health Cos Inc.
F Hoffmann-la Roche Ltd
Ionis Pharmaceuticals
Mylan Pharma Inc.
Sun Pharmaceutical Industries Inc
Orion Pharma A/S
AB Science SA

Report Scope

In this report, the Global Amyotrophic Lateral Sclerosis (ALS) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type

Rilutek (Riluzole)
Edaravone (Radicava)

Amyotrophic Lateral Sclerosis (ALS) Market, By Treatment Type

Physical Therapy
Speech Therapy
Medication
Respiratory Therapy
Others

Amyotrophic Lateral Sclerosis (ALS) Market, By End-Users

Hospitals & Clinics
Research and Academic institutes
others

Amyotrophic Lateral Sclerosis (ALS) Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amyotrophic Lateral Sclerosis (ALS) Market.

Available Customizations:

Global Amyotrophic Lateral Sclerosis (ALS) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Type (Rilutek (Riluzole), Edaravone (Radicava))
- 5.2.2. By Treatment Type (Physical Therapy, Speech Therapy, Medication, Respiratory Therapy, Others)
- 5.2.3. By End-Users (Hospitals & Clinics, Research and Academic institutes, others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Amyotrophic Lateral Sclerosis (ALS) Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Type
- 6.2.2. By Treatment Type
- 6.2.3. By End-Users
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Type
    - 6.3.1.2.2. By Treatment Type
    - 6.3.1.2.3. By End-Users
- 6.3.2. Canada Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Type
    - 6.3.2.2.2. By Treatment Type
    - 6.3.2.2.3. By End-Users
- 6.3.3. Mexico Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Type
    - 6.3.3.2.2. By Treatment Type
    - 6.3.3.2.3. By End-Users

7. Europe Amyotrophic Lateral Sclerosis (ALS) Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Type
- 7.2.2. By Treatment Type
- 7.2.3. By End-Users
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Type
    - 7.3.1.2.2. By Treatment Type
    - 7.3.1.2.3. By End-Users
- 7.3.2. France Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Type
    - 7.3.2.2.2. By Treatment Type
    - 7.3.2.2.3. By End-Users
- 7.3.3. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug Type
    - 7.3.3.2.2. By Treatment Type
    - 7.3.3.2.3. By End-Users
- 7.3.4. Italy Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Type
    - 7.3.4.2.2. By Treatment Type
    - 7.3.4.2.3. By End-Users
- 7.3.5. Spain Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Type
    - 7.3.5.2.2. By Treatment Type
    - 7.3.5.2.3. By End-Users

8. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Type
- 8.2.2. By Treatment Type
- 8.2.3. By End-Users
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Type
    - 8.3.1.2.2. By Treatment Type
    - 8.3.1.2.3. By End-Users
- 8.3.2. India Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Type
    - 8.3.2.2.2. By Treatment Type
    - 8.3.2.2.3. By End-Users
- 8.3.3. Japan Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Type
    - 8.3.3.2.2. By Treatment Type
    - 8.3.3.2.3. By End-Users
- 8.3.4. South Korea Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Type
    - 8.3.4.2.2. By Treatment Type
    - 8.3.4.2.3. By End-Users
- 8.3.5. Australia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Type
    - 8.3.5.2.2. By Treatment Type
    - 8.3.5.2.3. By End-Users

9. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Type
- 9.2.2. By Treatment Type
- 9.2.3. By End-Users
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Type
    - 9.3.1.2.2. By Treatment Type
    - 9.3.1.2.3. By End-Users
- 9.3.2. UAE Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Type
    - 9.3.2.2.2. By Treatment Type
    - 9.3.2.2.3. By End-Users
- 9.3.3. South Africa Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Type
    - 9.3.3.2.2. By Treatment Type
    - 9.3.3.2.3. By End-Users

10. South America Amyotrophic Lateral Sclerosis (ALS) Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Type
- 10.2.2. By Treatment Type
- 10.2.3. By End-Users
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Type
    - 10.3.1.2.2. By Treatment Type
    - 10.3.1.2.3. By End-Users
- 10.3.2. Colombia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Type
    - 10.3.2.2.2. By Treatment Type
    - 10.3.2.2.3. By End-Users
- 10.3.3. Argentina Amyotrophic Lateral Sclerosis (ALS) Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Type
    - 10.3.3.2.2. By Treatment Type
    - 10.3.3.2.3. By End-Users

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Amyotrophic Lateral Sclerosis (ALS) Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Sanofi S.A.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Brainstorm Cell Therapeutics Inc.
15.3. Biogen Inc.
15.4. Bausch Health Cos Inc.
15.5. F Hoffmann-la Roche Ltd
15.6. Ionis Pharmaceuticals
15.7. Mylan Pharma Inc.
15.8. Sun Pharmaceutical Industries Inc
15.9. Orion Pharma A/S
15.10. AB Science SA